

Gene Wallenstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5450098/publications.pdf>

Version: 2024-02-01

6
papers

2,133
citations

1477746

6
h-index

1872312

6
g-index

6
all docs

6
docs citations

6
times ranked

1511
citing authors

#	ARTICLE	IF	CITATIONS
1	Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. <i>International Journal of Rheumatology</i> , 2017, 2017, 1-15.	0.9	29
2	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2013, 159, 253.	2.0	381
3	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013, 65, 559-570.	6.7	481
4	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. <i>Lancet</i> , The, 2013, 381, 451-460.	6.3	610
5	A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. <i>Arthritis and Rheumatism</i> , 2012, 64, 970-981.	6.7	293
6	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 2012, 64, 617-629.	6.7	339